Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.
Laura J. Esserman, MD, MBA
Advertisement
Articles by Laura J. Esserman, MD, MBA
Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the elements of the I-SPY 2 trial in breast cancer.
Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.
Advertisement
Latest Updated Articles
Dr. Esserman Discusses the I-SPY 2 Trial in Breast CancerPublished: October 9th 2018 | Updated:
Dr. Esserman on the Elements of the I-SPY 2 Trial in Breast CancerPublished: January 30th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5